Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,401–4,500 of 15,747
Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents
Smatti, M. K., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.802312 · Cited by 28
Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.
Coban, M., Morrison, J. M., Maharjan, S., Hernandez Medina, D. H., Li, W., Zhang, Y. S., Freeman, W. D., Radisky, E. S., Roch, K. G. L., Weisend, C. M., et al. (2021) · eScholarship (California Digital Library) · Cited by 22
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 32
“Additionally, the long-term safety and efficacy of mRNA vaccines are still being studied, as this technology is relatively new [23,24].”
van Helmond, N., Brobyn, T. L., LaRiccia, P. J., Cafaro, T., Hunter, K. M., Roy, S., Bandomer, B., Ng, K. Q., Goldstein, H., Mitrev, L. V., et al. (2022) · Nutrients · doi:10.3390/nu15010180 · Cited by 22
“To assess the influence of COVID-19 vaccination, secondary analyses were performed on incidence rates including only the observation period after a worker was fully vaccinated (14 days after the second dose of an mRNA vaccine [42,43] or after the first dose of the non-mRNA Ad26.”
MethodSalaikumaran, M. R., Kasamuthu, P. S., Aathmanathan, V. S., & Burra, P. V. L. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-16445-3 · Cited by 24
“The major disadvantage of Pfizer/BioNtech Comirnaty vaccine is its stringent cold chain requirement though it has shown very good titers 37 .”
BackgroundAlghamdi, A., Alkazemi, A., Alissa, A. S., Alghamdi, I., Alwarafi, G., & Waggas, H. A. (2021) · Intervirology · doi:10.1159/000519456 · Cited by 25
Zhou, Q., Liu, Y., Zeng, F., Meng, Y., Liu, H., & Deng, G. (2023) · Vaccines · doi:10.3390/vaccines11040789 · Cited by 22
“Vaccination has become the paramount method for the prevention of worse outcomes, including severe COVID-19 and death during or in SARS-CoV-2 infection [1].”
BackgroundMethodHarnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 32
Single-step discovery of high-affinity RNA ligands by UltraSelex
Zhang, Y., Jiang, Y. Y., Kuster, D., Ye, Q., Huang, W., Fürbacher, S., Zhang, J., Doll, P., Lin, W., Dong, S., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01868-6 · Cited by 24
“For the doped SELEX experiments described in Supplementary Note 1, the respective library progenitor sequence (103 nt; Supplementary Table 2) was diversified by resynthesis using a phosphoramidite mixture (original base:three other bases = 85:5:5:5) for all positions of the former random region.”
InfluentialCOVID-19, circadian rhythms and sleep: from virology to chronobiology
Liu, Z., Ting, S., & Zhuang, X. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0043 · Cited by 24
“However, the ability of these vaccines to reduce the incidence of COVID-19 varies considerably [21,22].”
BackgroundTorabi, F., Bedston, S., Lowthian, E., Akbari, A., Owen, R. K., Bradley, D., Agrawal, U., Collins, P. W., Fry, R. J., Griffiths, L. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20118-6 · Cited by 28
Lee, S. Y. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02235-0 · Cited by 37
“One of the most standard applications of predictive probability approach for regulatory submission is the interim analysis for futility stopping (i.e., early stopping the trial in favor of the null hypothesis) [23, 105–107].”
BackgroundMethodInfluentialToniutto, P., Cussigh, A., Cmet, S., Bitetto, D., Fornasiere, E., Fumolo, E., Fabris, M., D’Aurizio, F., Fabris, C., Grillone, L., et al. (2022) · Liver International · doi:10.1111/liv.15331 · Cited by 22
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Lambe, T., Spencer, A. J., Thomas, K. M., Gooch, K. E., Thomas, S. R., White, A., Humphries, H. E., Wright, D., Belij‐Rammerstorfer, S., Thakur, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02443-0 · Cited by 24
Self-citationKian, W., Zemel, M., Kestenbaum, E. H., Rouvinov, K., Alguayn, W., Levitas, D., Ievko, A., Michlin, R., Abod, M. A., Massalha, I., et al. (2022) · Medicine · doi:10.1097/md.0000000000028561 · Cited by 20
Dang, F., Bai, L., Dong, J., Hu, X., Wang, J., Paulo, J. A., Xiong, Y., Liang, X., Sun, Y., Chen, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh7668 · Cited by 25
Heald, A. H., Stedman, M., Horne, L., Rea, R. D., Whyte, M., Gibson, M., Anderson, S. G., & Ollier, W. (2021) · Diabetic Medicine · doi:10.1111/dme.14774 · Cited by 22
Rao, R. P., Musante, C. J., & Allen, R. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00269-6 · Cited by 24
“COVID-19 vaccines are highly efficacious [2-5], there is a residual risk of severe cases of COVID-19 for unvaccinated and/or high risk populations [6,7].”
Cohn, E., Chimowitz, M., Long, T. G., Varma, J. K., & Chokshi, D. A. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00196-7 · Cited by 24
Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement
Coban, M. A., Morrison, J. M., Maharjan, S., Medina, D. H. H., Li, W., Zhang, Y. S., Freeman, W. D., Radisky, E. S., Roch, K. G. L., Weisend, C. M., et al. (2021) · Biomolecules · doi:10.3390/biom11060787 · Cited by 28
Capponi, M., Pulvirenti, F., Cinicola, B. L., Brindisi, G., Conti, M. G., Colaiocco, G., Castro, G. D., Guido, C. A., Duse, M., Midulla, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10071056 · Cited by 23
“Among local reactions, injection site pain was the most frequently reported AR, while among systemic events, asthenia and headache were the most commonly reported, confirming the results of pivotal clinical trials in both children aged 5 to 11 years [17] and in adults/adolescents [23,28,29].”
ResultA Multidisciplinary Approach to Coronavirus Disease (COVID-19)
Ertürk, A. G., Şahin, A., Ay, E. B., Pelit, E., Bağdatlı, E., Kulu, I., Gül, M., Mesci, S., Eryılmaz, S., Ilter, S. O., et al. (2021) · Molecules · doi:10.3390/molecules26123526 · Cited by 24
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Kakkassery, H., Carpenter, E., Patten, P., & Irshad, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.07.006 · Cited by 24
Lund, L. C., Støvring, H., Pottegård, A., Andersen, M. T., & Hallas, J. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.02.012 · Cited by 26
“The exposure of interest was immunization with the BNT162b2 vaccine (22), and we considered individuals exposed from the day of administration of a second dose, i.”
Haynes, B. F., Wiehe, K. J., Alam, S. M., Weissman, D., & Saunders, K. O. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000820 · Cited by 23
Bhardwaj, S. D., Choudhary, M. L., Jadhav, S., Vipat, V., Ghuge, R., Salvi, S., Kulkarni, R., Kinikar, A. A., Padbidri, V., Bafna, S., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.936634 · Cited by 23
Deng, J., Fukushima, Y., Nozaki, K., Nakanishi, H., Yada, E., Terai, Y., Fueki, K., & Itaka, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091785 · Cited by 29
Rechavi, Y., Shashar, M., Lellouche, J., Yana, M., Yakubovich, D., & Sharon, N. (2021) · Vaccines · doi:10.3390/vaccines9090977 · Cited by 23
“[10], where injection site pain, redness, and swelling were classified as local, and any other adverse reactions were classified as systemic.”
BackgroundInfluentialBaek, D. W., Hwang, S., Kim, J., Lee, J. M., Cho, H. J., Moon, J. H., Hwang, N., Jeong, J. Y., Lee, S.-W., & Sohn, S. K. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.2010801 · Cited by 22
Wong, L. P., Alias, H., Tan, Y. R., & Tan, K. M. (2021) · International Journal of Older People Nursing · doi:10.1111/opn.12436 · Cited by 26
SARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 24
Simader, E., Tobudic, S., Mandl, P., Haslacher, H., Perkmann, T., Nothnagl, T., Sautner, J., Radner, H., Winkler, F., Burgmann, H., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221347 · Cited by 23
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice
Chaparian, R. R., Harding, A. T., Hamele, C. E., Riebe, K. J., Karlsson, A., Sempowski, G. D., Heaton, N. S., & Heaton, B. E. (2022) · Journal of Virology · doi:10.1128/jvi.00689-22 · Cited by 26
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 27
“Since RNA-based vaccines have been licensed for use in humans for the first time and have shown excellent safety and effectiveness profiles, this platform is leading the way in the rapid development of vaccinations against emerging cases [39–41].”
Kotaki, R., Moriyama, S., Oishi, S., Onodera, T., Adachi, Y., Sasaki, E., Ishino, K., Morikawa, M., Takei, H., Takahashi, H., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp9927 · Cited by 29
Suzuki, Y., Shibata, Y., Minemura, H., Nikaido, T., Tanino, Y., Fukuhara, A., Kanno, R., Saito, H., Suzuki, S., Inokoshi, Y., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00949-3 · Cited by 26
Choi, H. K., Zhang, Y., & Dalbeth, N. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00804-5 · Cited by 24
CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
Amir, G., Rotstein, A., Razon, Y., Beer, G., Barak‐Corren, Y., Godfrey, M. E., Lakovsky, Y., Yaeger-Yarom, G., Yarden‐Bilavsky, H., & Birk, E. (2022) · Pediatric Cardiology · doi:10.1007/s00246-022-02878-0 · Cited by 25
“Since its introduction, the The Pfzer–BioNTech mRNA BNT162b2 COVID-19 vaccine has been shown to significantly decrease rates of infection, severe disease, and death due to COVID-19 infection, while side effects of the vaccine have been mild and mostly selflimiting [2, 3].”
BackgroundRacial/Ethnic Inequity in Transit-Based Spatial Accessibility to COVID-19 Vaccination Sites
Liu, D., Kwan, M., Kan, Z., Song, Y., & Li, X. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01339-x · Cited by 25
“(2020) found that a two-dose regimen of BNT162b2 mRNA Covid-19 Vaccine developed by Pfizer-BioNTech was 95% effective in preventing COVID-19 for individuals 16 years old or above [6].”
BackgroundTherapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis
Johnson, S. D., Olwenyi, O. A., Bhyravbhatla, N., Thurman, M., Pandey, K., Klug, E., Johnston, M., Dyavar, S. R., Acharya, A., Podany, A. T., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i29.4763 · Cited by 25
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 28
“These nAbs directed to the S protein are important for viral clearance and are a correlate for protection from infection/reinfection in animal challenge models and human vaccine trials [4-7].”
BackgroundBarmettler, S., DiGiacomo, D. V., Yang, N. J., Lam, T., Naranbhai, V., Dighe, A. S., Burke, K. E., Blumenthal, K. G., Ling, M. F., Hesterberg, P. E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.03.017 · Cited by 23
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 25
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440862 · Cited by 22
“…induction of antigen-specific CD4+ T cells as a possible contributor to the protection observed in clinical trials as early as two weeks after the first vaccine dose (Baden et al., 2020; Polack et al., 2020), when neutralizing antibody levels are still low in many individuals (Goel et al., 2021).”
BackgroundGonzález, S. M., Siddik, A. B., & Su, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612807 · Cited by 23
“Nonetheless, in this model, it is not clear if the pathogenesis was caused by reduced ACE2 and Ang (1-7) expression and activity in the brain or the increase of Ang II and/or ACE2 ectodomains in the cerebrospinal fluids.”
BackgroundInfluentialTop, K. A., Chen, R. T., Levy, O., Ozonoff, A., Carleton, B., Crawford, N. W., Creech, C. B., Kochhar, S., Poland, G. A., Gutu, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac407 · Cited by 23
Sekizawa, A., Hashimoto, K., Kobayashi, S., Kozono, S., Kobayashi, T., Kawamura, Y., Kimata, M., Fujita, N., Ono, Y., Obuchi, Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.963393 · Cited by 21
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines
Peng, Y., Zhang, L., Mok, C. K. P., Ching, J. Y. L., Zhao, S., Wong, M. K. L., Zhu, J., Chen, C., Wang, S., Yan, S., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01629-8 · Cited by 26
Iwai, S., Takayama, K., Sora, D., et al. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.2001541 · Cited by 22
“BNT162b2, a nucleoside-modified mRNA that encodes a SARS-CoV-2 spike glycoprotein stabilized in its prefusion conformation, has been authorized for emergency use for the prevention of COVID-19.”
BackgroundMethodInfluentialEffects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review
Minamimoto, R., & Kiyomatsu, T. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01076 · Cited by 22
“The two major mRNA-based vaccines, produced by Moderna and Pfizer/BioNTech, are 94-95% effective and there have been no critical safety concerns to date (7,8).”
BackgroundAdvances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Tsatsakis, A. M., Vakonaki, E., Tzatzarakis, M. N., Flamourakis, M., Νikolouzakis, Τ. Κ., Poulas, K. A., Papazoglou, G., Hatzidaki, E., Papanikolaou, N., Drakoulis, N., et al. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5033 · Cited by 21
Li, X., Cui, Z., Fan, H., Chen, Q., Cao, L., Qiu, H., Zhang, N., Xu, Y., Zhang, R., Chao Hui, Z. H. O. U., et al. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100221 · Cited by 23
Hulme, W. J., Williamson, E., Green, A. C. A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068946 · Cited by 24
“Three models were fit for each outcome, with progressive adjustment for confounders: (1) adjusting for region-specific calendar-time effects, by including a 2-knot restricted cubic spline for the date of vaccination and its interaction with region; (2) additionally adjusting for demographic characteristics; (3) additi…”
MethodGomes, D., Beyerlein, A., Katz, K., Hoelscher, G., Nennstiel, U., Liebl, B., Überla, K., & von Kries, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259370 · Cited by 25
“The COVID-19 disease vaccination programme in Germany was launched on Dec 27, 2020 using the BioNTech-Pfizer mRNA BNT162b2 [8] vaccine which requires two doses within at least 21 days for full protection [9].”
MethodSARS-CoV-2 (COVID-19) Variants and COVID-19 Vaccine Efficacy
Cheepsattayakorn, A. (2021) · Open Access Journal of Pulmonary & Respiratory Sciences · doi:10.23880/oajprs-16000135 · Cited by 21
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 26
Gui, Y., Li, X., Li, J., Shen, M., Zhang, M., Cao, Y., Xu, H., Li, H., Cheng, J., Pan, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104586 · Cited by 23
Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 29
Larijani, M. S., Sorouri, R., Eybpoosh, S., Doroud, D., Moradi, L., Ahmadinezhad, M., Bavand, A., Ashrafian, F., Namini, P. T., Zali, M., et al. (2023) · Pathogens and Disease · doi:10.1093/femspd/ftad010 · Cited by 20
Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivityPreprint
Yao, W., Ma, D., Wang, H., Tang, X., Du, C., Pan, H., Li, C., Lin, H., Farzan, M., Zhao, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.27.428353 · Cited by 22
Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
Jahrsdörfer, B., Groß, R. M., Seidel, A., Wettstein, L., Ludwig, C., Schwarz, T., Körper, S., Rojewski, M., Lotfi, R., Weinstock, C., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100036 · Cited by 22
Therapeutic approaches to Epstein–Barr virus cancers
Soldan, S. S., Messick, T. E., & Lieberman, P. M. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101260 · Cited by 26
Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
Nyankerh, C. N. A., Boateng, A. K., & Appah, M. (2022) · Vaccines · doi:10.3390/vaccines10060941 · Cited by 24
“Despite the tendency for the vaccines to prevent people from getting severely ill from COVID-19, serious adverse events following vaccination have been widely reported and are carefully being monitored [4,5].”
BackgroundInfluentialRNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
Birgaoanu, M., Sachse, M., & Gatsiou, A. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07391-3 · Cited by 26
“The most notable mentions are the two mRNA vaccines developed for the prevention of COVID-19 [75, 76].”
BackgroundDickens, B. S. L., Koo, J. R., Lim, J. T., et al. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab088 · Cited by 22
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 26
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 26
“Although the utilization of synthetic mRNA in vaccines is relatively new (described first in 1993 [6], injected in patients [33–35] and myself (Figure 1) [29] in the mid-2000s, and approved first in 2020 [9]), the utilization of natural mRNA to vaccinate is ancient: the yellow fever, mumps, measles, and rubella vaccin…”
BackgroundMethodInfluentialCOVID-19 vaccine and pregnancy: A safety weapon against pandemic
Magon, N., Prasad, S., Mahato, C., & Sharma, J. B. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2022.02.005 · Cited by 25
“In another study [19], people 16 years and older, a two-dose regimen of BNT162b2 provided 95 percent protection against COVID-19.”
BackgroundImmunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
Naruse, H., Ito, H., Izawa, H., Sarai, M., Ishii, J., Sakaguchi, E., Murakami, R., Ando, T., Fujigaki, H., & Saito, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235498 · Cited by 23
“The BNT162b2 mRNA COVID-19 vaccine has shown promising efficacy and safety, mainly in people without apparent pre-existing comorbidities [4,5].”
BackgroundVaccine Hesitancy Against SARS-CoV-2 in Health Personnel of Northeastern Mexico and Its Determinants
Castañeda-Vásquez, D. E., Ruíz-Padilla, J. P., & Botello-Hernández, E. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002205 · Cited by 25
Acute myocarditis associated with COVID-19 vaccination: A case report
Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., Yokoyama, T., & Kaneko, Y. (2022) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2021.11.006 · Cited by 22
“Some previous studies have also reported adverse events afer COVID-19 vaccination [3] .”
InfluentialKantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 26
“In the Phase 3 clinical trial, a total of 43,448 participants were enrolled: 21,720 receiving BNT162b2 and 21,728 receiving the placebo.(100) A two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in persons 16 years of age or older.”
BackgroundVinh, D. C., Gouin, J., Cruz-Santiago, D., Canac‐Marquis, M., Bernier, S., Bobeuf, F., Sengupta, A., Brassard, J.-P., Guerra, A., Dziarmaga, R., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00012-5 · Cited by 31
Park, J. Y., Lee, J.-Y., & Yi, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11010238 · Cited by 22
Al-Mutairi, N., Almutairi, A. N., Almazyad, M., & Alwazzan, S. (2022) · Dermatologic Therapy · doi:10.1111/dth.15521 · Cited by 31
Microfluidics for Nanomedicine Delivery
Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 26
Efficacy and Safety of Vaccinations in Geriatric Patients: A Literature Review
Ciarambino, T., Crispino, P., Buono, P., Giordano, V., Trama, U., Iodice, V., Leoncini, L., & Giordano, M. (2023) · Vaccines · doi:10.3390/vaccines11091412 · Cited by 25
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 29
“8% of trial participants developing moderate and severe side effects after receiving the second dose of the Moderna vaccine, respectively (32, 33).”
BackgroundCOVID-19 and the liver: What do we know so far?
Nasa, P., & Alexander, G. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i5.522 · Cited by 23
Keep, S., Stevenson-Leggett, P., Dowgier, G., Everest, H., Freimanis, G., Oade, M. S., Hammond, J. A., Armesto, M., Vila, R., Bru, T., et al. (2022) · Journal of Virology · doi:10.1128/jvi.02059-21 · Cited by 20
COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects
Quiroga, B., Sánchez-Álvarez, E., Goicoechea, M., & de Sequera, P. (2021) · Journal of Healthcare Quality Research · doi:10.1016/j.jhqr.2021.05.002 · Cited by 22
“655 Arthralgia, n (%) 2 (<1) 1 (1) 1 (<1) 0.”
Aksyuk, A. A., Bansal, H., Wilkins, D. E., Stanley, A. M., Sproule, S., Maaske, J., Sanikommui, S., Hartman, W. R., Sobieszczyk, M. E., Falsey, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100882 · Cited by 25
Gupta, S. L., Mantus, G. E., Manning, K. E., Ellis, M. L., Patel, M., Ciric, C. R., Lu, A., Turner, J. S., O’Halloran, J. A., Presti, R. M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00582-22 · Cited by 23
“The Pfizer (BNT162b2) vaccine is a lipid nanoparticle-based mRNA vaccine that encodes full-length spike protein and is given at 30 mg/dose with a 21-day interval for adults (9).”
BackgroundWu, J., Ma, M., Miao, Y., Ye, B., Li, Q., Tarimo, C. S., Wang, M., Gu, J., Wei, W., Zhao, L., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.796467 · Cited by 25
The Impact of SARS-CoV-2 Infection on Fertility and Female and Male Reproductive Systems
Markiewicz-Gospodarek, A., Wdowiak, P., Czeczelewski, M., Forma, A., Flieger, J., Januszewski, J., Radzikowska-Büchner, E., & Baj, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194520 · Cited by 26
mRNA Vaccine - A New Cancer Treatment Strategy
Tan, T., Deng, S., Wu, B.-H., Yang, Q., Wu, M., Wu, H., Cao, C., & Xu, C. S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230222124424 · Cited by 26
Mohamed, Y., El‐Maradny, Y. A., Saleh, A. K., Nayl, A. A., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113499 · Cited by 23
“The lipid nanoparticle-encapsulated mRNA-based vaccines BNT162b2 and mRNA1273 encode the full-length SARS-CoV-2 spike [91,92].”
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 23
Sedegah, M., Porter, C. K., Goguet, E., Ganeshan, H. D., Belmonte, M., Huang, J., Belmonte, A. D., Inoue, S., Acheampong, N., Malloy, A. M. W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276241 · Cited by 24
“Group 2 (n = 179) participants had no documented SARS-CoV-2 infection by qPCR but had received either the Pfizer-BioNTech BBNT162b2 COVID-19 vaccine [32] (full two dose series: n = 177, approximately 21 days apart [Mean 21.”
MethodCurrent Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 28
“The data showed that mRNA-based COVID-19 vaccines had high efficacy in protecting against symptomatic and severe illnesses caused by ancient strains and pre-Omicron variants in phase III clinical trials [93, 94].”
Iavarone, M. A., Tosetti, G., Facchetti, F., Topa, M., Lim, J. M. E., Hang, S. K., Licari, D., Lombardi, A., D’Ambrosio, R., Degasperi, E., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.09.010 · Cited by 20
“[5] Polack FP, Thomas SJ, Kitchin N, et al.”
BackgroundAkintunde, T. Y., Chen, S., Musa, T. H., Amoo, F. O., Adedeji, A., Ibrahim, E. A., Tassang, A. E., Musa, I. H., & Musa, H. H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1969851 · Cited by 26
“Overall, high-quality articles based on the citation score explore the core of research in COVID-19 and Vaccine safety which was published by Polack et al., 2020 under the title “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine” with received total citation (TC) = 1229 citations scores,…”
BackgroundPublic Health Needs the Public Trust: A Pandemic Retrospective
Halma, M. T. J., & Guetzkow, J. (2023) · BioMed · doi:10.3390/biomed3020023 · Cited by 26
“While symptomatic infection was the original endpoint of the clinical trial used in the Emergency Use Authorization (EUA) of the COVID vaccines [125,126], it was later stated that the vaccines were primarily intended to reduce hospitalization and death [127].”
BackgroundMethodVision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019
Choi, M., Seo, M.-H., Choi, K.-E., Lee, S., Choi, B., Yun, C., Kim, S., & Kim, Y. Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123318 · Cited by 21
“Conversely, the BNT162b2 is a lipid nanoparticle formulated nucleoside-modified RNA encoding the SARS-CoV-2 full-length spike protein [19].”
BackgroundThe COVID-19 Vaccine: Why the Hesitancy?
Grossman, V. A. (2021) · Journal of Radiology Nursing · doi:10.1016/j.jradnu.2021.02.011 · Cited by 25
The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review
Cherif, Y. Y. S., Djeffal, C., Serhan, H. A. A., El-Nahhas, A. S. A., Yousef, H., Katamesh, B. E., Abdelazeem, B., & Abdelaal, A. (2022) · Vaccines · doi:10.3390/vaccines11010069 · Cited by 25
“This might be explained by the fact that the highest immune response usually occurs during the first ten days [84].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.